Hikma Pharmaceuticals Full Year 2022 Earnings: EPS Misses Expectations

·1-min read

Hikma Pharmaceuticals (LON:HIK) Full Year 2022 Results

Key Financial Results

  • Revenue: US$2.52b (down 1.4% from FY 2021).

  • Net income: US$188.0m (down 55% from FY 2021).

  • Profit margin: 7.5% (down from 17% in FY 2021).

  • EPS: US$0.84 (down from US$1.82 in FY 2021).

HIK Post-Clinical Trial Products

  • Approved (during full year): 270.

  • Launched (during full year): 182.


All figures shown in the chart above are for the trailing 12 month (TTM) period

Hikma Pharmaceuticals EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 45%.

Looking ahead, revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Pharmaceuticals industry in the United Kingdom.

Performance of the British Pharmaceuticals industry.

The company's shares are down 5.6% from a week ago.

Risk Analysis

You should learn about the 3 warning signs we've spotted with Hikma Pharmaceuticals.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here